The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of the National Institute of Clinical Excellence (NICE)

British Journal of Cancer

Volumn 87, Issue 5, 2002, Pages 481-490

  Waters, J S ^a   O'Brien, M E R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Lung cancer; NICE; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; TENIPOSIDE; VINBLASTINE; VINDESINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DRUG CHOICE; DRUG EFFICACY; HAIR LOSS; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; INFORMED CONSENT; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY; TOXICITY TESTING; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EUROPE; GREAT BRITAIN; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PACLITAXEL; PALLIATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0037183687     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600491     Document Type: Review

References (65)

1. Cisplatin/Gemcitabine (CG) vs Cisplatin/Gemcitabine/Vinorelbine (CGV) vs Sequential Doublets of Gemcitabine/Vinorelbine followed by Ifosfamide/Vinorelbine (GV/IV) in advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish lung cancer group phase III trial (GEPC/98-02)
2. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer
3. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study
4. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
5. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
6. Cisplatin-Gemcitabine, vs. Cisplatin-Gemcitabine- Vinorelbine, vs. Cisplatin-Gemcitabine-Paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial
7. Preliminary results of a randomised phase III trial comparing four cisplatin (P) based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC)
8. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer
9. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)
10. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
11. A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): A study of the Umbrian Lung Cancer Group
12. Mitomycis, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
13. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
14. A randomised study of Gemcitabine with Carboplatin (GC) Versus Mitomycin, Vinblastine and Cisplatin (MVP) or Mitomycin C, Ifosfamide and Cisplatin (MIC) as first line chemotherapy in advanced Non-Small Cell Lung Cancer (NSCLC)
15. Phase III trial of Neo-Adjuvant Chemotherapy (NCT) in resectable stage I (except T1N0), II, IIIa Non-Small Cell Lung Cancer (NSCLC): The French experience
16. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
17. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
18. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
19. Spanish lung cancer group randomised trial of preoperative chemotherapy (Cisplatin either 50mg/m2 or 100 mg/m2) in stage IIIA (N2) non-small cell lung cancer
20. Docetaxel + Cisplatin (DC) and Docetaxel + Carboplatin (DCB) vs Vinorelbine + Cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer: Results of a multicenter, randomized phase III study
21. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
22. Gemcitabine + Vinorelbine (GV) yields better survival than Vinorelbine (V) alone in elderly Non-Small Cell Lung Cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial
23. A randomised phase III trial of the Southern Italy Oncology Group (GOIM) of mitomycin C plus vindesine and cisplatin (MVP regimen) versus vinorelbine plus cisplatin (PV regimen) in stage III-IV non small cell lung cancer
24. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
25. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
26. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
27. Phase III study of Navelbine versus Navelbine plus cisplatin in non-small cell lung cancer stage IIIb or IV
28. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules
29. Mitomycin C, vinblastine and carboplatin: Effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung
30. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study
31. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: Gemcitabine + Vinorelbine vs Vinorelbine and vs Gemcitabine in elderly advanced NSCLC patients
32. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer
33. Variation in survival of patients with lung cancer in Europe, 1985-1989
34. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study
35. E1594-A randomized phase III trial in metastatic Non-Small Cell Lung Cancer (NSCLC)-outcome of PS 2 patients (Pts): An Eastern Cooperative Group Trial (ECOG)
36. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
37. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861
38. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma
39. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced Non Small Cell Lung Cancer (NSCLC). A preliminary analysis
40. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multi-center trial including 612 patients
41. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer
42. Single-agent versus combination chemotherapy in advanced non small cell lung cancer: A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness
43. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
44. Gemcitabine as a single agent in the treatment of elderly patients with stage IIIb and IV non-small cell lung cancer; preliminary results of an Italian multicentre phase II study
45. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
46. An economic analysis of southwest oncology group trial S9509: Cisplatin/Vinorelbine vs Carboplatin/Paclitaxel for advanced non small cell lung cancer
47. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
48. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study
49. A multicenter, randomized phase III study of Docetaxel + Cisplatin (DC) and Docetaxel + Carboplatin (DCB) Vs. Vinorelbine + Cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer
50. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
51. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer
52. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer
53. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
54. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer
55. A randomized phase III trial of four chemotherapy regimens in advanced Non-Small Cell Lung Cancer (NSCLC)
56. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
57. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
58. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
59. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer
60. Duration of therapy in stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A Multi-institutional phase III trial
61. Glob 1: Final results of a prospective randomized phase III trial comparing Vinorelbine and Cisplatin (NP) versus Vinorelbine, Ifosfamide, and Cisplatin (NIP) in metastatic Non Small Cell Lung Cancer (NSCLC) patients
62. Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
63. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy
64. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer
65. Symptom control in advanced Non-Small Cell Lung Cancer (NSCLC): A multicenter prospective randomized phase III study of single agent Gemcitabine (GEM) versus Cisplatin-Vindesine (PV)